Cargando…

Diagnostic markers for community-acquired pneumonia

Community-acquired pneumonia (CAP) is one of the respiratory infectious diseases caused by not only bacteria, but also viruses. Antibiotic agents are needed to treat only bacterial but not viral CAP. In addition, there are some non-infectious respiratory diseases in the differential diagnosis of CAP...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Akihiro, Ishida, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290537/
https://www.ncbi.nlm.nih.gov/pubmed/32566635
http://dx.doi.org/10.21037/atm.2020.02.182
_version_ 1783545700099817472
author Ito, Akihiro
Ishida, Tadashi
author_facet Ito, Akihiro
Ishida, Tadashi
author_sort Ito, Akihiro
collection PubMed
description Community-acquired pneumonia (CAP) is one of the respiratory infectious diseases caused by not only bacteria, but also viruses. Antibiotic agents are needed to treat only bacterial but not viral CAP. In addition, there are some non-infectious respiratory diseases in the differential diagnosis of CAP, such as malignant diseases, interstitial lung diseases, pulmonary edema, and pulmonary hemorrhage. We usually diagnose patients having CAP by comprehensive evaluation of symptoms, vital signs, laboratory examinations, and radiographic examinations. However, symptoms and vital signs are not specific for the diagnosis of CAP; therefore, we also use inflammatory biomarkers for differentiating bacterial from viral CAP and non-infectious respiratory diseases. We have used the white blood cell count, C-reactive protein (CRP), and erythrocyte sedimentation rate as common inflammatory biomarkers, but they are not specific for bacterial infection because they could be increased by malignant diseases and collagen diseases. Recently, some inflammatory biomarkers such as procalcitonin (PCT), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), pro-adrenomedullin (proADM), and presepsin have been developed as relatively specific biomarkers for bacterial infection. Many reports have evaluated the usefulness of PCT for diagnosing CAP. In this review, the characteristics of each biomarker are discussed based on previous studies.
format Online
Article
Text
id pubmed-7290537
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-72905372020-06-19 Diagnostic markers for community-acquired pneumonia Ito, Akihiro Ishida, Tadashi Ann Transl Med Review Article on Advances in Laboratory Tests for Infectious Diseases Community-acquired pneumonia (CAP) is one of the respiratory infectious diseases caused by not only bacteria, but also viruses. Antibiotic agents are needed to treat only bacterial but not viral CAP. In addition, there are some non-infectious respiratory diseases in the differential diagnosis of CAP, such as malignant diseases, interstitial lung diseases, pulmonary edema, and pulmonary hemorrhage. We usually diagnose patients having CAP by comprehensive evaluation of symptoms, vital signs, laboratory examinations, and radiographic examinations. However, symptoms and vital signs are not specific for the diagnosis of CAP; therefore, we also use inflammatory biomarkers for differentiating bacterial from viral CAP and non-infectious respiratory diseases. We have used the white blood cell count, C-reactive protein (CRP), and erythrocyte sedimentation rate as common inflammatory biomarkers, but they are not specific for bacterial infection because they could be increased by malignant diseases and collagen diseases. Recently, some inflammatory biomarkers such as procalcitonin (PCT), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), pro-adrenomedullin (proADM), and presepsin have been developed as relatively specific biomarkers for bacterial infection. Many reports have evaluated the usefulness of PCT for diagnosing CAP. In this review, the characteristics of each biomarker are discussed based on previous studies. AME Publishing Company 2020-05 /pmc/articles/PMC7290537/ /pubmed/32566635 http://dx.doi.org/10.21037/atm.2020.02.182 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article on Advances in Laboratory Tests for Infectious Diseases
Ito, Akihiro
Ishida, Tadashi
Diagnostic markers for community-acquired pneumonia
title Diagnostic markers for community-acquired pneumonia
title_full Diagnostic markers for community-acquired pneumonia
title_fullStr Diagnostic markers for community-acquired pneumonia
title_full_unstemmed Diagnostic markers for community-acquired pneumonia
title_short Diagnostic markers for community-acquired pneumonia
title_sort diagnostic markers for community-acquired pneumonia
topic Review Article on Advances in Laboratory Tests for Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290537/
https://www.ncbi.nlm.nih.gov/pubmed/32566635
http://dx.doi.org/10.21037/atm.2020.02.182
work_keys_str_mv AT itoakihiro diagnosticmarkersforcommunityacquiredpneumonia
AT ishidatadashi diagnosticmarkersforcommunityacquiredpneumonia